BWTHydra Brings in 22M in Series D to Push First Program into Clinic.qxd

First Page		Document Content
Date: 2009-01-21 17:10:08 AstraZeneca MedImmune Business Venture capital TRPV Transient receptor potential channel Pfizer Ion channels Membrane biology Biology		BWTHydra Brings in 22M in Series D to Push First Program into Clinic.qxd Add to Reading List Source URL: www.hydrabiosciences.com Download Document from Source Website File Size: 77,95 KB Share Document on Facebook

	B’SYS GmbH CHO TRPV1 Cell Line Specification Sheet © B’SYS GmbH DocID: 1q9uB - View Document
	Microsoft Word - Session_01-Cellular and Molecular Pharmacology.doc DocID: 1fDjk - View Document
	Technische Regeln für die Bemessung und die Ausführung punktförmig gelagerter Verglasungen (TRPV) - Schlussfassung August 2006 Veröffentlicht in den Mitteilungen des Deutschen Instituts für Bautechnik, Ausgabe März DocID: 1e5Js - View Document
	PHE377: A novel clinical-stage TRPV1 antagonist devoid of “class” side effects for the treatment of chronic pain syndromes Summary of the Opportunity PharmEste wishes to identify a partner for development and commerc DocID: 1aagi - View Document
	Hydra Biosciences and Pfizer Global Research & Development Sign Collaboration Agreement -- Leverages Hydra’s Proprietary Ion Channel Technology in the Area of Pain Cambridge, MA, July 26, Hydra Biosciences anno DocID: 1a5Tv - View Document